The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Exenatide (Exendin-4)–Induced Pancreatitis
Abstract
Exenatide is a 39–amino acid peptide approved for the adjunctive treatment of type 2 diabetes. It is an incretin mimetic agent that is consistent in activity with the actions of glucagon-like peptide 1. Proposed mechanisms of action include enhanced glucose-dependent insulin secretion from pancreatic β-cells, restoration of first-phase insulin response, suppression of glucagon secretion, and delay of gastric emptying. Kendall et al. (1) found no evidence of cardiovascular, pulmonary, hepatic, or renal toxicities with exenatide. Nausea (39–48%) and hypoglycemia (19–27%) were the most common side effects reported. A 69-year-old man with type 2 diabetes of 15 years’ duration presented for follow-up. He had known diabetic neuropathy and retinopathy. His medical history was remarkable for coronary artery disease, gastroesophageal reflux disease, rheumatoid arthritis, and …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acute pancreatitis following exenatide administration has been documented in case reports since 2006 [50].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [50]
Citations
Cites
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Cited by
Sorted by citations
Items 101–141 of 141
Cheng, Z., Wang, S., Li, F., Jin, C., Mo, C., Zheng, J., Li, X., Liang, F., Yang, J.-K., & Gu, D. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70013 · Cited by 9
Wangnoo, S. K., Kumar, S., Bhattacharyya, A., Tripathi, S., Akhtar, S., Shetty, R., & Ghosal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189232 · Cited by 8
Opinion on the Use of Animal Models in Nonclinical Safety Assessment: Pros and Cons
Sura, R., Hutt, J. A., & Morgan, S. J. (2021) · Toxicologic Pathology · doi:10.1177/01926233211003498 · Cited by 8
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Development of GLP-1 secretagogue using microarray in enteroendocrine L cells
Kim, K., & Jang, H.-J. (2016) · BioChip Journal · doi:10.1007/s13206-016-0403-5 · Cited by 7
Bhattacharjee, B., Chakrovorty, A., Biswas, M., Samadder, A., & Nandi, S. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230519112312 · Cited by 7
Mizukami, H., Inaba, W., Takahashi, K., Kamata, K., Tsuboi, K., & Yagihashi, S. (2013) · Pancreas · doi:10.1097/mpa.0b013e318287c9b5 · Cited by 7
Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects
Lebovitz, H. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0274 · Cited by 7
Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature
Patel, D. M., Patel, M. M., Patel, V. B., Patel, V. B., Patel, M. V., & Patel, D. K. (2024) · Current Drug Safety · doi:10.2174/0115748863324787240916114833 · Cited by 6
Zhang, J., Wu, J., Zeng, W., Zhao, Y., & Zu, H. (2015) · PubMed Central · Cited by 6
Hart, N. J., Weber, C. S., Papas, K. K., Limesand, S. W., Vágner, J., & Lynch, R. M. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00209.2018 · Cited by 6
Multivalent γ‐PGA‐Exendin‐4 Conjugates to Target Pancreatic β‐Cells
Rossi, L., Kerekes, K., Kovács‐Kocsi, J., Körhegyi, Z., Bodnár, M., Fazekas, E., Prépost, E., Pignatelli, C., Caneva, E., Nicotra, F., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200196 · Cited by 4
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 4
Los nuevos antidiabéticos en el punto de mira… ¿razones de seguridad o caza de brujas?
Nicolau, J., & Masmiquel, L. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.11.002 · Cited by 3
Zhou, Y., Zhu, J., Wu, H., Deng, Y., & Ji, Q. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01139-2 · Cited by 3
Management of Glycemia in Diabetic Patients with Stage IV and V Chronic Kidney Disease
Roche-Recinos, A., Charlap, E., & MARKELL, M. S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0600-y · Cited by 3
Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice
Ni, Z., Wang, B., Ma, X., Duan, H., Jiang, P., Li, X., Wei, Q., Ji, X., & Li, M. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-2166-9 · Cited by 3
Management of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Oyedemi, S. O., Ibeh, R. C., Kayode, O. T., Ikechukwu, G. C., Coopoosamy, R. M., & Lawal, M. M. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.09.051 · Cited by 2
The new antidiabetic agents in the firing line… safety reasons or witch hunt?
Nicolau, J., & Masmiquel, L. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.11.003 · Cited by 2
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00042-5 · Cited by 2
Schwab, S., & Diem, P. (2009) · Therapeutische Umschau · doi:10.1024/0040-5930.66.10.677 · Cited by 2
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide
Koro, C. E., Pientka, J., Bainbridge, V., O’Donnell, N., Stender, M., & Stemhagen, A. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0128-3 · Cited by 2
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 2
Sitagliptin-associated Acute Pancreatitis: A Case Report
Tsai, L.-Y., Ma, W.-Y., Hsia, T., Pei, D., & Su, C. (2011) · 內科學誌 · doi:10.6314/jimt.2011.22(4).06 · Cited by 1
Diabetes or Diabetes Drugs: A Cause for Acute Pancreatitis
Olansky, L. (2012) · InTech eBooks · doi:10.5772/25445 · Cited by 1
Incretin-Based Therapy and Pancreatitis—What is the Risk?
Sternthal, E. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.334 · Cited by 1
A practical Guide to Treatment with Liraglutide
Devendra, D., & Bravis, V. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s4148 · Cited by 1
„Glucagon-like peptide-1“-basierende Therapie
Ritzel, R. A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0698-8
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Seguridad de los fármacos basados en incretinas
Esmatjes, E. (2011) · Avances en Diabetología · doi:10.1016/j.avdiab.2011.09.005
Andréasson, S. (2015) · Epsilon Archive for Student Projects (University of Southampton)
La terapia del diabete mellito tipo 2 basata sulle incretine
Prato, S. D., Sesti, G., Bonora, E., Bosi, E., Consoli, A., Cucinotti, D., Ghirlanda, G., Giorgino, F., Lauro, D., Marchetti, P., et al. (2008) · CINECA IRIS Institutial research information system (University of Pisa)
Safety of incretin‐based therapies for type 2 diabetes
Davis, T. M. E. (2011) · The Medical Journal of Australia · doi:10.5694/mja11.10648
Can drugs used in type 2 diabetes therapy induce acute pancreatitis?
Borowik, A., Hrycek, A., Chudek, J. T., & Olszanecka‐Glinianowicz, M. (2011) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.964936
Simvastatin-Induced Acute Pancreatitis: A rare side effect of a statin
Suwansiripat, S., Saengpattrachai, M., Shivawongsri, S., Choomduang, P., & Kukreja, R. (2013) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2013.09.013
Ananthakrishnan, K. (2016) · UA Campus Repository (The University of Arizona)
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Metadata
- Authors
- Denker, P. S., & Dimarco, P. E.
- Affiliations
- Largo HCA Diabetes Center, Clearwater, Florida
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-02-01
- Volume
- 29
- Issue
- 2
- Pages
- 471-471
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2029214914
- Cited by
- 140
- References
- 1
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 8 · 2015: 9 · 2014: 17 · 2013: 15 · 2012: 12
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- exenatide, exendin-4, pancreatitis, type 2 diabetes, incretin mimetics, glucagon-like peptide-1, adverse drug reactions, drug-induced pancreatitis
- MeSH terms
- Exenatide, Acute Disease, Aged, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Pancreatitis, Peptides, Venoms, Abdominal Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
